We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
+10.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$466M
AUM Growth
-$255M
(-35%)
Cap. Flow
-$296M
Cap. Flow
% of AUM
-63.44%
Top 10 Holdings %
Top 10 Hldgs %
56.9%
Holding
92
New
18
Increased
13
Reduced
21
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$9.79M |
| 2 |
FIVE9
FIVN
|
+$5.96M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$5.67M |
| 4 |
Generac Holdings
GNRC
|
+$5.66M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$4.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$41.8M |
| 2 |
AstraZeneca
AZN
|
+$31.2M |
| 3 |
Sanofi
SNY
|
+$28.8M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$26.4M |
| 5 |
Merck
MRK
|
+$25.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.42% |
| 2 | Technology | 2.22% |
| 3 | Industrials | 2% |
| 4 | Communication Services | 0.09% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Relmada Therapeutics
RLMD
$557M
| – | – |
-193,230
| Closed | -$7.15M |
|
|
77
PUT
Relmada Therapeutics
RLMD
$557M
| – | – |
-93,000
| Closed | -$3.44M |
|
78
Sunrun
RUN
$2.34B
| – | – |
-65,000
| Closed | -$1.79M |
|
79
CALL
SentinelOne
S
$6.53B
| – | – |
-164,800
| Closed | -$4.21M |
|
|
80
SentinelOne
S
$6.53B
| – | – |
-280,000
| Closed | -$7.16M |
|
81
SolarEdge
SEDG
$2.51B
| – | – |
-29,426
| Closed | -$6.81M |
|
82
Teva Pharmaceuticals
TEVA
$40.8B
| – | – |
-776,346
| Closed | -$6.77M |
|
83
CALL
Unity
U
$13.8B
| – | – |
-367,500
| Closed | -$11.7M |
|
|
84
Unity
U
$13.8B
| – | – |
-11,500
| Closed | -$366K |
|
|
VRNA
85
DELISTED
Verona Pharma
VRNA
| – | – |
-120,000
| Closed | -$1.23M |
|
86
WIX.com
WIX
$2.3B
| – | – |
-129,000
| Closed | -$10.1M |
|
|
PSTX
87
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| – | – |
-300,000
| Closed | -$1.06M |
|
|
DICE
88
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-152,913
| Closed | -$3.1M |
|
|
DICE
89
PUT
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-150,000
| Closed | -$3.04M |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q4 2022 Portfolio in Review
As of Q4 2022, Sphera Funds Management held 92 positions worth $466M, down 35% from $720M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sphera Funds Management withdrew a net $296M in Q4 2022, closing 28 positions and reducing 21 holdings. Its most notable exit was Palo Alto Networks, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.
Against the trend, Sphera Funds Management opened a new position in FIVE9 worth $6.45M.
- Sphera Funds Management's largest Q4 2022 buy was FIVE9: 95,000 shares worth $6.45M.
- Sphera Funds Management added most to CinCor Pharma, Inc. Common Stock in Q4 2022, an estimated $9.79M increase.
- Sphera Funds Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $41.8M.
- Sphera Funds Management fully exited Palo Alto Networks in Q4 2022, selling an estimated $10.3M.
- Sphera Funds Management's ten largest holdings make up 57% of its $466M portfolio in Q4 2022.
- Sphera Funds Management opened 18 new positions and closed 28 in Q4 2022.
- Sphera Funds Management's portfolio value fell 35% quarter-over-quarter to $466M.
Based on Sphera Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.